These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
238 related items for PubMed ID: 25534557
1. [Impact of a targeted educational intervention on respiratory syncytial virus bronchiolitis prevention in full-term and preterm infants]. Bernard L, Lecomte B, Pereira B, Proux A, Boyer A, Sautou V. Arch Pediatr; 2015 Feb; 22(2):146-53. PubMed ID: 25534557 [Abstract] [Full Text] [Related]
2. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis. Frogel MP, Stewart DL, Hoopes M, Fernandes AW, Mahadevia PJ. J Manag Care Pharm; 2010 Feb; 16(1):46-58. PubMed ID: 20131495 [Abstract] [Full Text] [Related]
4. Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016-2017 epidemic season: a systematic review of seven Italian reports. Cutrera R, Wolfler A, Picone S, Rossi GA, Gualberti G, Merolla R, Del Vecchio A, Villani A, Midulla F, Dotta A. Ital J Pediatr; 2019 Nov 09; 45(1):139. PubMed ID: 31706338 [Abstract] [Full Text] [Related]
6. Severe respiratory syncytial virus bronchiolitis: epidemiologic variations associated with the initiation of palivizumab in severely premature infants with bronchopulmonary dysplasia. Grimaldi M, Gouyon B, Michaut F, Huet F, Gouyon JB, Burgundy Perinatal Network. Pediatr Infect Dis J; 2004 Dec 09; 23(12):1081-5. PubMed ID: 15626942 [Abstract] [Full Text] [Related]
7. Respiratory syncytial virus morbidity and outpatient palivizumab dosing in South Carolina, 2004-2009. Chadha AD, Bao W, Holloway J, Mann J, Rye AK, Brown DE. South Med J; 2012 Aug 09; 105(8):399-404. PubMed ID: 22864095 [Abstract] [Full Text] [Related]
10. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics; 1998 Sep 09; 102(3 Pt 1):531-7. PubMed ID: 9738173 [Abstract] [Full Text] [Related]
11. Adherence to Palivizumab for Respiratory Syncytial Virus Prevention in the Canadian Registry of Palivizumab. Chan P, Li A, Paes B, Abraha H, Mitchell I, Lanctôt KL, CARESS investigators. Pediatr Infect Dis J; 2015 Dec 09; 34(12):e290-7. PubMed ID: 26780032 [Abstract] [Full Text] [Related]
12. Preventing RSV bronchiolitis in vulnerable infants: the role of palivizumab. Fitzgerald DA. Paediatr Respir Rev; 2009 Sep 09; 10(3):143-7. PubMed ID: 19651385 [Abstract] [Full Text] [Related]
13. Medical utilization associated with palivizumab compliance in a commercial and managed medicaid health plan. Diehl JL, Daw JR, Coley KC, Rayburg R. J Manag Care Pharm; 2010 Sep 09; 16(1):23-31. PubMed ID: 20044844 [Abstract] [Full Text] [Related]
15. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program. Wegner S, Vann JJ, Liu G, Byrns P, Cypra C, Campbell W, Stiles A. Pediatrics; 2004 Dec 09; 114(6):1612-9. PubMed ID: 15574623 [Abstract] [Full Text] [Related]
16. Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey. Oncel MY, Mutlu B, Kavurt S, Baş AY, Demirel N, Akyol M, Erdeve O, Dilmen U. Turk J Pediatr; 2012 Dec 09; 54(4):344-51. PubMed ID: 23692714 [Abstract] [Full Text] [Related]
18. Palivizumab use in preterm neonates. Kingston S, Murphy BP. Ir Med J; 2010 May 09; 103(5):141-4. PubMed ID: 20666085 [Abstract] [Full Text] [Related]